Examining the risks and benefits of replacing traditional dose-response with hormesis.

Hum Exp Toxicol

Comparative Toxicology Laboratories, Department of Diagnostic Medicine/Pathobiology, 1800 N Denison Avenue, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506-5705, USA.

Published: May 2005

In responding to Drs Calabrese and Baldwin's question, 'At what point, if ever, should hormesis be employed as the principal dose response default assumption in risk assessment?', we examined the benefits of replacing traditional dose-response with hormesis. In general, hormesis provides more complete useful information for risk assessment than does traditional dose-response. A major limitation of using hormesis as a default assumption in risk estimation is the difficulty of differentiating complex low-level hormetic responses from the placebo effect. A second limitation is that hormesis merely further defines one response. Most toxicoses have many responses. The most complete information takes all responses and their connections into account.

Download full-text PDF

Source
http://dx.doi.org/10.1191/0960327105ht521oaDOI Listing

Publication Analysis

Top Keywords

traditional dose-response
12
benefits replacing
8
replacing traditional
8
dose-response hormesis
8
default assumption
8
assumption risk
8
limitation hormesis
8
hormesis
6
examining risks
4
risks benefits
4

Similar Publications

Association between remnant cholesterol (RC) and endometriosis: a cross-sectional study based on NHANES data.

Lipids Health Dis

January 2025

Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

Background: Prior research indicates a potential link between dyslipidemia and endometriosis (EMs). However, the relationship between remnant cholesterol (RC) and EMs has not been thoroughly investigated. Consequently, looking into and clarifying the connection between RC and EMs was the primary goal of this study.

View Article and Find Full Text PDF

Advanced ovarian cancer often presents with multiple lesions exhibiting varying responses to chemotherapy, highlighting the critical influence of the tumor microenvironment (TME). This study investigates the phenomenon of chemotherapeutic hormesis, wherein low doses of chemotherapeutic agents, such as cisplatin (CDDP) and paclitaxel (PTX), paradoxically stimulate rather than inhibit cancer cell proliferation. Our findings indicate that NOS3 ovarian cancer cells, particularly drug-resistant variants, exhibit enhanced proliferation when exposed to low concentrations of these drugs.

View Article and Find Full Text PDF

Purpose: Triple-negative breast cancer (TNBC) is a disease associated with high incidence and high mortality, which is a major problem threatening women's health. Xiaoyao Sanjie Decoction (XYSJD) exhibits remarkable therapeutic efficacy on TNBC; however, the underlying mechanism is unclear. This study verified the efficacy of XYSJD and its active component in the treatment of TNBC and explored its potential mechanism.

View Article and Find Full Text PDF

Aim: This study aimed to determine the maximum tolerated dose (MTD) of the urokinase plasminogen activator (uPA) inhibitor upamostat (LH011) in combination with gemcitabine for locally advanced unresectable or metastatic pancreatic cancer.

Method: Seventeen patients were enrolled and received escalating doses of oral LH011 (100, 200, 400, or 600 mg) daily alongside 1000 mg/m of gemcitabine. Safety profiles, tumor response (including response rate and progression-free survival), pharmacokinetics, and changes in CA199 and D-dimer levels were assessed.

View Article and Find Full Text PDF

Objective: He Shi Yu Lin Formula (HSYLF) is a clinically proven prescription for treating premature ovarian insufficiency (POI), and has shown a good curative effect. However, its molecular mechanisms are unclear. This study aimed to investigate the molecular mechanisms of HSYLF and clarify how network pharmacology analysis guides the design of animal experiments, including the selection of effective treatment doses and key targets, to ensure the relevance of the experimental results.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!